Search clinical trials for: LAF237 (vildagliptin)

Total 191 results

Novartis Pharmaceuticals

Completed

Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin

Type-2 Diabetes Mellitus

Hong Kong
Novartis Pharmaceuticals

Completed

VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Spain, Poland, South Africa, Taiwan, Hong Kong, Norway, Italy, Bulgaria, Latvia, Lithuania, Germany, Turkey, Argentina, Israel, Korea, Republic of, Dominican Republic, Guatemala, Brazil, Colombia, Peru, Philippines, Russian Federation and more
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia

Diabetes Mellitus, Type 2

Switzerland, Germany
Novartis

Completed

Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese Volunteers

Healthy

China
Novartis Pharmaceuticals

Completed

Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)

Type 2 Diabetes

China
Novartis

Completed

Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers

Healthy

China
Mayo Clinic
Novartis Pharmaceuticals

Completed

The Effects of LAF237 on Gastric Function in Type 2 Diabetes

Diabetes Mellitus, Non-Insulin-Dependent

United States
Novartis

Completed

Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

Type-2 Diabetes

Germany, United States
Novartis Pharmaceuticals

Completed

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients

Type 2 Diabetes Mellitus (T2DM)

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis

Terminated

Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Novartis Pharmaceuticals

Completed

Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2

Taiwan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China, Thailand, Philippines, Singapore
Novartis Pharmaceuticals

Completed

Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function (CGM-VISIT)

Diabetes Mellitus Type 2

Germany
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy (CLMF237A1303)

Diabetes Mellitus, Type 2

Japan
Azienda Ospedaliero-Universitaria di Parma

Completed

Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes

Type 2 Diabetes

Italy
Laboratorios Silanes S.A. de C.V.

Recruiting

Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure

Type 2 Diabetes

Mexico
Novartis Pharmaceuticals

Completed

Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

Type II Diabetes Mellitus | Congestive Heart Failure

Russian Federation, Singapore, Italy, Czechia, Lithuania, Germany, Guatemala, India, Denmark, Estonia, Slovakia, Romania, Latvia, Greece, Poland
Novartis

Completed

Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy

Type 2 Diabetes Mellitus

China
Novartis Pharmaceuticals

Completed

Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Bio-innova Co., Ltd

Not yet recruiting

Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets

Healthy Subjects
Radboud University Medical Center

Completed

Vildagliptin and Endothelium-dependent Vasodilatation

Type 2 Diabetes | Endothelial Dysfunction

Netherlands
Peking University

Unknown

Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients (VISA-T2DM)

Obesity | Diabetes Mellitus, Type 2

China
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany, United States
Novartis Pharmaceuticals

Completed

A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Switzerland
Ziv Hospital

Unknown

Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)

Non-Alcoholic Fatty Liver Disease

Israel
Novartis

Completed

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Novartis Pharmaceuticals

Completed

A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Diabetes Mellitus, Type 2

Germany
Novartis

Completed

Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Novartis

Completed

A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Novartis

Completed

Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis Pharmaceuticals

Completed

Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Type 2 Diabetes Mellitus

Egypt
University of Campania "Luigi Vanvitelli"

Completed

DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes

Chronic Foot Ulcers

Italy
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%

Diabetes Mellitus, Type 2

Switzerland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin

Diabetes Mellitus, Type 2

Germany, Switzerland
International Bio service

Not yet recruiting

The Bioequivalence Study of Fixed-dose Combination of Vildagliptin and Metformin HCI 50/1000 mg FCT Under Fed Conditions

Healthy Volunteer
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients. (BENEFIT)

Type 2 Diabetes Mellitus

Germany
Novartis

Completed

A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

Thailand
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Novartis

Completed

Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany

3

Subscribe